Role of corticosteroid therapy in IgA nephropathy; where do we stand?
| Autor: | Srikanth Prasad, Uday Venkat Mateti, Rajeevalochana Parthasarathy, Mahesha Vankalakunti, Shankar Prasad Nagaraju, Sindhura Lakshmi Koulmane Laxminarayana, Dharshan Rangaswamy, Vasudeva Guddattu, Ravindra Prabhu Attur, Srinivas Shenoy, Karan Saraf, Aswani Srinivas Mareddy, Sindhu Kaza |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Nephrology
medicine.medical_specialty Proteinuria medicine.diagnostic_test business.industry medicine.medical_treatment 030232 urology & nephrology Urology Renal function Immunosuppression 030204 cardiovascular system & hematology urologic and male genital diseases medicine.disease Nephropathy 03 medical and health sciences 0302 clinical medicine Internal medicine Biopsy Cohort medicine Stage (cooking) medicine.symptom business |
| Zdroj: | Journal of Nephropathology. 6:368-373 |
| ISSN: | 2251-8819 2251-8363 |
| DOI: | 10.15171/jnp.2017.61 |
| Popis: | Background: Current KDIGO guidelines suggest corticosteroids (CS) administration in IgA nephropathy (IgAN) with persistent proteinuria >1 g/d despite 3-6 months of supportive care and estimated glomerular filtration rate (eGFR) >50 mL/min/1.73 m2 . The benefits of CS in patients with eGFR 50 mL/min/1.73 m2 . Patients and Methods: A cohort of biopsy proven primary IgAN diagnosed between March 2010 - February 2015 who received oral CS with minimum follow-up of 6 months were included. They were categorized into two groups according to their eGFR (group 1 - eGFR 50 mL/min/1.73 m2 ). The eGFR and urine protein creatinine ratio (UPCR) were followed up at entry, 6 months, 12 months and at the end of follow-up. Outcomes studied were change in eGFR, proteinuria and progression to end-stage renal disease (ESRD). Results: Out of 44 patients, 23 were in group1 and 21 patients in group 2. At the end of follow-up, similar reduction of proteinuria (UPCR) was observed in both groups (P=0.62). However, group 1 had a significant fall in eGFR compared to improvement in group 2 (P=0.004). One in each group has reached CKD stage 5 (P=0.73). Conclusions: Addition of CS to conservative treatment in IgAN patients with initial eGFR 50 mL/min/1.73 m2 ). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|